**South San Francisco, CA – November 15, 2021** – PACT Pharma, Inc., a clinical-stage company developing transformational personalized neoTCR-T cell therapies for the eradication of solid tumors, today announced that new data related to its PACTImmune™ Database were presented at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting. The results were featured in a poster presentation (#820) entitled, “Machine learning significantly improves neoantigen-HLA predictions utilizing > 26,000 data points from the PACTImmune Database,” at the SITC conference, which was held November 10-14, 2021. 

The presented results reported findings from a study in which PACT applied machine learning to more than 26,000 manufactured polypeptides consisting of the initially predicted neoE peptide together with Beta-2-Microglobulin and the HLA heavy chain for 62 different HLA alleles. Data demonstrated that PACT’s approach significantly improved neoE-HLA predictions, resulting in a 22% improvement in success rates on prospective data as compared to the widely used netMHCpan4.1 predictions. Additionally, the presentation outlined key elements of PACT’s strategy for continued enhancements to its approach to further improve its predictive power. 

“The PACTImmune Database enables us to tune and continue to learn from our platform and its growing data assets. Based on retrospective analysis we know that higher predicted neoE-HLA success corelates with more TCRs captured per patient. Ultimately, these improved predictions should give us more actionable neoTCR options for patients in our clinical trial,” said Eric Stawiski, Vice President of Bioinformatics at PACT and presenter of the SITC poster.

The abstract related to this presentation is available on the SITC website and can be accessed at: [https://jitc.bmj.com/content/9/Suppl_2/A858](https://jitc.bmj.com/content/9/Suppl_2/A858).

**About PACTImmune™ Database**
PACT has developed a proprietary approach to validate predicted neoepitopes (neoEs) and their cognate T cell receptors (neoTCRs) by capturing neoepitope-specific T cells from peripheral blood. This neoTCR discovery and validation process is being applied in a clinical trial (NCT03970382) evaluating personalized neoTCR-T cell therapy to treat patients across eight solid tumor types. Extensive pre-, on- and post-treatment data related to this trial has been accumulated in the PACTImmune Database (PIDB) which represents a growing data asset for patient-specific tumor immunogenicity in solid tumors.

**About PACT Pharma, Inc.**
PACT is a clinical-stage biopharmaceutical company pioneering individualized, non-viral precision genome engineered, tumor-specific T cell therapies for the treatment of patients with solid cancers. PACT is now enrolling patients in its first-in-human Phase 1 clinical trial.

Each person's cancer emerges with a private signature of mutations. PACT identifies these cancer mutation targets (neoantigens) for each person, biochemically verifies and captures T cells from their blood and uses its proprietary, cutting edge (non-viral) precision genome engineering technologies to manufacture a personalized immune cell therapy product for each person with cancer.

For more information, please visit [www.pactpharma.com](https://www.pactpharma.com).

Contacts:

**PACT Pharma**
Atulya Agarwal 
atulya@pactpharma.com

**Vida Strategic Partners (on behalf of PACT Pharma)**
Tim Brons (Media)
415-675-7402
tbrons@vidasp.com


PACT Reports New Data Highlighting Predictive Power of Machine Learning Approach Leveraging PACTImmune™ Database at Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting

**South San Francisco – January 11, 2021** – PACT Pharma, Inc., a clinical-stage company developing transformational personalized neoTCR-T cell therapies for the eradication of solid tumors, today announced that the company will present at the 39th Annual J.P. Morgan Healthcare Conference, which is being held virtually, on January 11, 2021 at 7:30 a.m. PT/10:30 a.m. ET.  

**About PACT Pharma**

PACT is a clinical-stage biopharmaceutical company pioneering individualized, non-viral precision genome engineered, tumor-specific T cell therapies for the treatment of patients with solid cancers. PACT is now enrolling patients in its first-in-human Phase 1 clinical trial. 

Each person's cancer emerges with a private signature of mutations. PACT identifies these cancer mutation targets (neoantigens) for each person, biochemically verifies and captures T cells from their blood and uses its proprietary, cutting edge (non-viral) precision genome engineering technologies to manufacture a personalized immune cell therapy product for each person with cancer.

For more information please visit[ www.pactpharma.com]( www.pactpharma.com). 


**Media Contact**

Sarah Sutton
Finsbury Glover Hering (FGH)
[ssutton@fgh.com](mailto:ssutton@fgh.com) 
202-337-0808

**Investor Contact**

Uneek Mehra
[umehra@pactpharma.com](mailto:umehra@pactpharma.com)


PACT Pharma to Present at the 39th Annual J.P. Morgan Healthcare Conference

Press Releases

- The round was led by Vida Ventures, a next generation life science venture firm with industry-leading experience in cell and gene therapy  
- The financing will be used to expand clinical & manufacturing development to deliver clinical data for patients with multiple solid tumor types  

SOUTH SAN FRANCISCO, Calif., Jan. 10, 2020 /PRNewswire/ — PACT Pharma, in pursuit of its vision to eradicate solid tumors using transformational, first-in-class fully personalized NeoTCR-T cell therapies, today announced that it has closed an oversubscribed $75 million Series C financing. This round, led by Vida Ventures, a next generation life science venture firm with industry-leading experience in the cell and gene therapy, also included current investors of PACT.  

Combined with proceeds from previous financings, PACT will use the Series C proceeds to expand the scope of its clinical plan to investigate NeoTCR-T cell products targeting multiple neoantigens for a spectrum of solid tumor types. In addition to clinical expansion, PACT will open in 2020 a next-gen GMP manufacturing facility in South San Francisco to support the end-to-end production and supply chain for the engineering of personalized neoantigen-targeted autologous T cells. Under the direction of industry veteran Tim Moore, President and Chief Technology Officer, PACT will leverage the new in-house manufacturing facility to automate manufacturing and analytic processes to reduce cycle time and manufacturing costs.  

“PACT has grown from company launch to opening its first-in-kind clinical trial in two years. Our progress has been exhilarating and the support from our existing investors has made that progress possible,” said Alex Franzusoff, PhD, Chief Executive Officer of PACT Pharma. “As we look to the next stage of our development and expansion of our clinical programs, we are excited to have interest from a new group of prominent investors who both understand the potential of NeoTCR-T cell therapy and have direct experience in the space. Vida Ventures stood out as a partner of choice, given their depth of operational experience in research, clinical development and manufacturing in cell therapy as well as their proven ability to guide companies like Kite and Allogene across key stages of development.  

As part of the Series C financing, Helen S. Kim, Managing Director at Vida Ventures, will join the Company’s Board of Directors. Ms. Kim brings over 25 years of biotechnology leadership experience and serves on the boards of Assembly Biosciences, Applied Molecular Transport, A2 Biotherapeutics and Exicure, Inc.  

“Our investment in PACT Pharma represents our goal to fund scientific advances by embracing cutting edge innovation with the potential to make a meaningful difference in the lives of patients,” said Kim. “PACT has developed a pioneering platform of personalized designer T cells with the potential to target some of the most elusive solid cancers facing society today.”  

**ABOUT PACT Pharma**  

PACT Pharma is an independent, privately funded clinical stage company, based in South San Francisco, California, developing transformational personalized neoTCR-T cell therapies for the eradication of solid tumors and is now enrolling patients in its first-in-human Phase 1 clinical studies at several key academic centers of the CIRM-funded Alpha Clinic network, in California.  

PACT Pharma’s distinguised co-founders, David Baltimore (Nobel Laureate), Antoni Ribas, Jim Heath, Terry Rosen and Juan Jaen launched the company in early 2017. The company is backed by GV (formerly Google Ventures), Canaan, Casdin Capital, Droia, Foresite Capital, Invus Opportunities, Pontifax and Wu Capital and is supported by investment from AbbVie Ventures and Taiho Ventures. PACT Pharma’s technology is designed to individually program tumor-exclusive targeting into each patient’s own immune system cells to eradicate their own cancer. The process, which is currently in Phase 1 clinical testing, involves taking a biopsy of a person’s cancer tissue to assess the tumor-exclusive mutations with predictive algorithms, then to biologically verify the optimal targets by capturing T cells from blood that already recognize the mutations. Using the T cell receptor information from the captured T cells, together with proprietary, cutting edge, (non-viral) precision genome engineering technologies, fresh patient T cells are edited in one step to craft tumor-specific neoTCR-P1 cells. These private designer T cells have been shown to immediately kill mutation-expressing tumors in pre-clinical studies, and to create a deep reservoir of ‘ready-to-go’ neoTCR-P1 cells with the potential for long term persistence to prevent future cancer recurrence. These developments offer PACT exceptional prospects to leverage the potential of ideal tumor targets and biologically verified neoTCRs into clinical development of neoTCR-T adoptive cell therapies.  

**CONTACT:** William Nevius, wnevius(at)canaan.com

PACT Pharma Raises $75M in Oversubscribed Series C Financing to Develop Fully Personalized NeoTCR-T Cell Therapies for Patients with Cancer

PACT is a company pushing the frontiers of science, technology and medicine. We are creating T cell therapies to alter the course of cancer and meaningfully impact the lives of patients who urgently need breakthrough therapies. We are building a team of driven, talented and passionate individuals committed to bringing these novel personalized therapies to people living with cancer.

Join Us

PACT is a clinical stage immuno-oncology company dedicated to engineering T cell therapies by seeking to harness the inherent biology and curative potential of each patient's immune system to treat their cancer and advance the field of immune-driven medicines.

Who We Are

PACT Pharma is an exciting, well-funded clinical stage company developing personalized adoptive T cell therapies for the eradication of solid tumors. Our private designer T cells are created by analyzing a patient’s individual tumor and engineering T cells to kill that specific tumor. If you desire a stimulating fast paced environment, working with intelligent people who are making an impact in cancer, you will want to join the PACT Pharma team.  We are a rapidly expanding, innovative, and collaborative workforce working towards one main goal, eradicating cancer!We are located in the San Francisco bay area. PACT Pharma offers a competitive compensation and benefits package, including participation in the aggressive growth of the company in the form of stock option grants.We are currently recruiting for a Bioprocess Manufacturing Specialist who will join our Manufacturing Team and continue advancing PACT’s cutting-edge engineered cell product. This will be a unique opportunity to see your ideas rapidly translate into the clinic and impact patient lives. Responsibilities:<ul><li style="line-height: normal;"> Perform cGMP processing and documentation required to produce and assess safe and efficacious products within an ISO clean room environment using aseptic techniques as applicable</li><li style="line-height: normal;"> Develop, update, and implement production and large-scale manufacturing procedures to optimize processes and regulatory requirements, such as standard operating procedures, batch records, etc.</li><li style="line-height: normal;"> Resolve or partner with cross-functional teams, such as Process Development (PD) and Manufacturing Sciences and Technology (MSAT), to scale-up and investigate technical issues, as well as maintenance of production equipment</li><li style="line-height: normal;"> Contribute to and/or own quality records (deviation, change controls, corrective and preventative actions) and complete in a timely manner</li><li style="line-height: normal;"> Provide justification and review existing operational and process discrepancies and provide technical expertise to improve procedures</li><li style="line-height: normal;"> Exercise a continuous improvement mindset to create or enhance Manufacturing tools, processes, documents, etc.</li><li style="line-height: normal;"> Provide manufacturing expertise for studies related to equipment and process performance, comparability, and reliability</li><li style="line-height: normal;"> Contribute to operating equipment specifications and improve manufacturing techniques</li><li style="line-height: normal;"> Evaluate, select and order equipment that is most appropriate and cost effective for the manufacture of company products</li></ul>Qualifications:<ul><li style="line-height: normal;"> Bachelor’s degree in a biologics, biotechnology, engineering, or related field with 5+ years of manufacturing or applicable experience in a cGMP environment</li><li style="line-height: normal;"> Clean room, aseptic, and/or biological safety cabinet experience required</li><li style="line-height: normal;"> Experience in one or more of the following required: <ul><li style="line-height: normal;"> Cell counting, cell culture/fermentation, chromatography, filtration, single use technologies</li></ul></li><li style="line-height: normal;"> Ability to communicate clearly and concisely, both verbally and in the form of written reports</li><li style="line-height: normal;"> Effective in solving and communicating manufacturing-related issues to relevant stakeholders</li><li style="line-height: normal;"> Demonstrated ability on filling the gaps between business requirements and suggesting reasonable alternatives when necessary</li><li style="line-height: normal;"> Ability to build partnerships with cross-functional teams without formal authority</li><li style="line-height: normal;"> Effective organizational skills, time management, and ability to coordinate workload and meet established deadlines</li><li style="line-height: normal;"> Flexible and able to adapt to company growth and evolving responsibilities</li><li style="line-height: normal;"> Ability to work a flexible schedule that may include nights, weekends and/or holidays</li><li style="line-height: normal;"> GLP and GMP experience a plus </li></ul>Physical Demands :The physical demands described here are representative of those that must be met by an employee to successfully perform the essential functions of the job. While performing the duties of this job, the employee is frequently required to stand; walk; sit; bend; stretch; use hands to finger, handle or feel; reach with hands and arms; and talk or hear. The employee is regularly required to climb or balance; stoop, kneel, or crouch. The employee is frequently required to lift and/or move up to 30 pounds. Non-absorbent gowning or laboratory coats are required, as well as latex (or a non-latex substitute) gloves. When working with potentially hazardous materials that may spray, aerosol, or otherwise contact skin or mucous membranes, face shields or goggles must be worn. Heavy cryo gloves must be used when working with liquid nitrogen.  PACT Pharma is proud to be an equal opportunity employer and strives to build a diverse and inclusive team. We do not discriminate on the basis of race, color, national origin, religion, gender, sexual orientation, age, marital status, veteran status, or disability status.

Corporate (South San Francisco)

Bioprocess Manufacturing Specialist

PACT Pharma is an exciting, well-funded clinical-stage company developing personalized adoptive T cell therapies for the eradication of solid tumors. Our private designer T cells are created by analyzing a patient&rsquo;s individual tumor and engineering T cells to kill that specific tumor.If you desire a stimulating fast-paced environment, working with intelligent people who are making an impact in cancer, you will want to join the PACT Pharma team.&nbsp; We are a diverse work family with a dynamic and earnest culture. We are a rapidly expanding, innovative, and collaborative workforce working towards one main goal, eradicating cancer!We are in the San Francisco bay area, the heart of the world&rsquo;s premier biotechnology research hub. PACT Pharma offers a competitive compensation and benefits package, including participation in the aggressive growth of the company in the form of stock option grants.We are currently recruiting for a Medical Monitoring Director who will report to Vice President, Clinical Development and continue advancing PACT Pharma&rsquo;s cutting-edge engineered cell product. This will be a unique opportunity to see your contributions to PACT Pharma&rsquo;s personalized process rapidly translate into the clinic and impact patient lives.The ideal candidate should be aware of techniques in the latest molecular cloning techniques and in mammalian cell culture. The candidate should enjoy operating in an exceptionally dynamic and cooperative environment and will communicate results to and coordinate efforts with a larger cross-disciplinary team of immunologists, biologists, engineers, and bio-informaticians.What You Will Do:<ul><li>Provide clinical oversight across all relevant studies and programs assumes a leadership role in ongoing clinical study team and relevant sub-team meetings, and clinical study communications internally and externally</li><li>Design and develop clinical studies</li><li>Serve as Medical Monitor on assigned PACT Pharma studies using the high-touch approach to work closely with site coordinators and PIs to manage patients on cell therapy studies</li><li>Collaborate with the development of the product safety profile, clinical sections of the IB, and other materials</li><li>Participate in the identification and selection of appropriate external investigators and sites</li><li>Conduct ongoing reviews of medical/safety data, interim analysis, and reporting of data</li><li>Responsible for any relevant abstract submissions, poster, oral presentations, and publications related to the assigned cell therapy product/indication(s)</li><li>Represent PACT Pharma in key investigator and other external presentations, meetings, and other communications</li><li>Play a lead role in the development and implementation of communications strategies to support existing and concluded studies. Includes KOL interactions, advisory boards, major medical meetings, congresses and other events, publications, and other materials</li><li>Work with regulatory and other internal partners/stakeholders in the completion and submission of regulatory filings and other regulatory documentation. Supports others with clinical science information and input for regulatory submissions and other regulatory processes.</li><li>Responsible to ensure that clinical development plans, objectives, and deliverables are consistently accomplished on time and on-target</li><li>Lead and/or otherwise represent clinical development (CD) in sub-teams (e.g. Study Management Teams) relevant to assigned cell therapy product/indication(s) and helps ensure cross-functional integration, coordination, and alignment to enable effective and efficient CD plan execution</li></ul>Minimal Qualifications:<ul><li>M.D. with oncology/cell therapy experience&nbsp;is required</li><li>4 + years pharma/biotech industry experience OR an academic appointment in the field</li><li>5 + years experience with clinical trials. In-depth understanding of all phases of drug development</li><li>Experience authoring aspects of a global clinical development plan or full clinical study protocol is preferred</li><li>Experience working with the principles and techniques of data analysis, interpretation, and clinical relevance</li><li>Versed in medical aspects of GCP (Good Clinical Practice), ICH (International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use), FDA, EMEA, NICE, and other relevant guidelines and regulations</li><li>Familiar with competitive activity in the field</li><li>Clinical leadership: is regarded as an expert in his/her field, is respected by others, can effectively contribute to longer-range drug development, and can lead cross-functional teams to successful results</li><li>Strong interpersonal, verbal communication, written and influencing skills: can influence without authority and has proven experience building and cultivating relationships with key partners and stakeholders, both internally and externally</li><li>Business presentation skills: effective at summarizing and presenting the key considerations and decision-points</li><li>Ability to travel globally (20-30%)</li></ul>&nbsp;Preferred Qualifications: <ul><li>Academic/teaching background is a plus</li><li>Experience submitting an NDA/BLA to regulatory authorities in Europe and/or the U.S. is preferred</li><li>Experience publishing results of a clinical drug trial in a referred journal is preferred</li><li>Previous people management experience is a plus</li></ul>&nbsp;PACT Pharma is proud to be an equal opportunity employer and strives to build a diverse and inclusive team. We do not discriminate based on race, color, national origin, religion, gender, sexual orientation, age, marital status, veteran status, or disability status.

Medical Monitoring Director

“I joined PACT to work with our impressive management team and innovative technologies to improve cancer therapies. It is the people that make this company exceptional and the mission to cure cancer that motivates me.”

thumbnail_Rebecca.jpg

Rebecca.jpg

Director

"I joined PACT because of the science and the people!  PACT is a special place where people work hard because they are passionate about the science, committed to patients, value teamwork and push the boundaries to never accept the status quo. For those who thrive in a fast paced and innovative environment, PACT provides a rewarding opportunity to tackle challenging projects in a collaborative way."

thumbnail_Susan.png

Susan.png

Vice President

“I joined PACT Pharma because I was energized by the people and the purpose of the organization and have been continuously impressed by the drive and ambition of the whole team to overcome any challenges. Being encouraged to be authentic with one another, and in all of our work, has really built a strong, unified team. This has been a unique and very rewarding experience for me.”

thumbnail_Brian_Birdi.jpg

Brian_Birdi.jpg

Associate Director

“When I first interviewed at PACT, I remember being impressed by the collaborative and open nature of research within the company. It left quite the impression with me and ultimately guided me towards choosing a career at PACT. Since joining, I am continually grateful for the level of openness and collaboration between teams and departments that is crucial for pioneering scientific work."


Accelerating CurativeT Cell Therapiesfor Cancer

Tailored for Each and Every Person

PACT Reports New Data Highlighting Predictive Power of Machine Learning Approach Leveraging PACTImmune™ Database at...

Who We Are

Mission & Vision

Our
Platform

Our
Programs

PACT Voices

Director

Technical Operations

Vice President

Program Management

Associate Director

Automation

Scientist

Tumor Immunology

Join Us

Bioprocess Manufacturing Specialist

Medical Monitoring Director

Accelerating CurativeT Cell Therapiesfor Cancer

Tailored for Each and Every Person

PACT Reports New Data Highlighting Predictive Power of Machine Learning Approach Leveraging PACTImmune™ Database at...

Who We Are

Mission & Vision

OurPlatform

OurPrograms

PACT Voices

Director

Technical Operations

Vice President

Program Management

Associate Director

Automation

Scientist

Tumor Immunology

Join Us

Bioprocess Manufacturing Specialist

Medical Monitoring Director

Our
Platform

Our
Programs